Ruibo Bio-B (06938) is included in the Hang Seng Composite Index and is expected to become the Hong Kong Stock Exchange Standard

Zhitong Finance App learned that on August 21, 2026, Hang Seng Index Company announced the results of the Hang Seng Index series of quarterly reviews up to June 30, 2026. Among them, Ruibo Bio-B (06938) was included in the Hang Seng Composite Index. Changes in the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly. Ruibo Bio-B (06938) may be transferred to the Hong Kong Stock Connect because it meets a range of standards including market value and liquidity.

Recently, Ruibo Bio-B announced that the group expects to obtain revenue of about 311 million to 436 million yuan in the first half of 2026, an increase of about 200% to 320% over the same period in 2025, mainly due to partial confirmation of licensing revenue under the exclusive global licensing cooperation between the Group and Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), as well as revenue confirmed when the Group cooperated with Boehringer Ingelheim International to reach milestones. The above cooperation all involved steatohepatitis associated with metabolic dysfunction. The development and commercialization of (MASH) small interfering RNA (siRNA) therapy formed the main driving force for the Group's revenue growth during the reporting period.